SCHEMBL302243

SCHEMBL302243

O=C(c1ccc(N(Cc2ccccc2)S(=O)(=O)c2ccc(F)cc2)cc1)N1CCN(c2ccccc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.62
KMT2A Q03164 3/20 0.61
HPGD P15428 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.60
HTT P42858 1/20 0.60
MAPT P10636 1/20 0.57
MEN1 O00255 2/20 0.55
SLC6A7 Q99884 1/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA7 P43166 1/20 0.55
CA9 Q16790 1/20 0.55
CA14 Q9ULX7 1/20 0.55
NR3C1 P04150 1/20 0.54
PTGES O14684 3/20 0.53
ALOX5 P09917 1/20 0.53
GAA P10253 1/20 0.52
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3282269 0.96 LMNA (0.68) LMNAKMT2AHPGDSMN1; SMN2HTT
SCHEMBL13065013 0.93 CNR2 (0.61) LMNAKMT2AHPGDSMN1; SMN2HTT
SCHEMBL303307 0.93 LMNA (0.71) LMNAKMT2AHPGDSMN1; SMN2HTT
SCHEMBL304647 0.91 LMNA (0.58) LMNAKMT2AHPGDSMN1; SMN2HTT
SCHEMBL303907 0.90 LMNA (0.65) LMNAKMT2AHPGDSMN1; SMN2HTT
SCHEMBL2813139 0.90 LMNA (0.62) LMNAKMT2AHPGDSMN1; SMN2HTT
SCHEMBL1711351 0.89 LMNA (0.62) LMNAKMT2AHPGDSMN1; SMN2HTT
SCHEMBL1711156 0.89 LMNA (0.62) LMNAKMT2AHPGDSMN1; SMN2HTT
SCHEMBL302427 0.89 KMT2A (0.68) LMNAKMT2AHPGDSMN1; SMN2HTT
SCHEMBL1711088 0.87 LMNA (0.59) LMNAKMT2AHPGDSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
JP-2012500834-A 2012-01-12 JP claimed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 LMNA 1683/4885KMT2A 777/4885HPGD 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.